TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00989079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
Study: NCT01877642

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine 10 mg
Description: Inhaled Staccato loxapine 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Placebo
Description: Inhaler with no drug in it to mimic the ADASUVE inhaler
Study: NCT00989079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
Study: NCT01877642

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Placebo
Description: Inhaler with no drug in it to mimic the ADASUVE inhaler

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Placebo
Description: Inhaler with no drug in it to mimic the ADASUVE inhaler

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Placebo
Description: Inhaler with no drug in it to mimic the ADASUVE inhaler

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Placebo
Description: Inhaler with no drug in it to mimic the ADASUVE inhaler

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Placebo
Description: Inhaler with no drug in it to mimic the ADASUVE inhaler
Study: NCT01877642

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IM
Description: intramuscular placebo to mimic lorazepam 1 mg IM

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IM
Description: intramuscular placebo to mimic lorazepam 1 mg IM

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IM
Description: intramuscular placebo to mimic lorazepam 1 mg IM

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IM
Description: intramuscular placebo to mimic lorazepam 1 mg IM

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IM
Description: intramuscular placebo to mimic lorazepam 1 mg IM

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IM
Description: intramuscular placebo to mimic lorazepam 1 mg IM
Study: NCT01818271

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community-based group rehabilitation
Description: Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~* Advanced dynamic tasks, including stepping and other transitional tasks to treadmill \& over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~* Treadmill walking exercise program.
Study: NCT00989079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
Study: NCT03825796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib Mesylate
Description: Given PO
Study: NCT00989079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
Study: NCT00852085

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced community service
Description: Two educational sessions and volunteering at a local community service site

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group MI
Description: Four group counseling sessions and two directed observational visits to an emergency department
Study: NCT04324879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525
Description: TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Study: NCT02166242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethaselen
Description: ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
Study: NCT01162499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39)
Description: IV infusion of exendin-(9-39) for 5 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-(9-39)
Description: IV infusion of exendin-(9-39) for 5 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
Study: NCT03825796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT00454363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03906617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve block and wound infiltration with liposomal bupivacaine
Description: Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 266mg of liposomal bupivacaine with 24 ml of 0.5% bupivacaine will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone
Description: Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.
Study: NCT01268982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket preservation
Description: sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket
Study: NCT02237469

Intervention type: RADIATION
Intervention: Prone and supine simulation
Description: Treatment planning in the two positions.
Study: NCT05428683

Intervention type: DRUG
Group type: OTHER
Intervention: intra-vitreal triamcinolone-moxifloxacin injection after cataract surgery as a prophylactic measures against post-operative endophthalmitis
Description: At the end of surgery, 4mg triamcinolone acetonide and 0.2mg moxifloxacin from 0.5 moxifloxacin preservative-free eye drop) were injected once inferotemporally 3.5 mm posterior to the limbus via pars plana into the vitreous cavity by using 30 G needle.
Study: NCT02588612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letetresgene autoleucel (GSK3377794)
Description: letetresgene autoleucel (GSK3377794) as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as a lymphodepleting chemotherapy.
Study: NCT05215977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW031
Description: The active ingredient of MW031 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU
Study: NCT01535417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shinbaro Capsule
Description: Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Study: NCT03248999

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: rectal swab
Description: stool samples by rectal swab
Study: NCT03955705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg/ml
Description: Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% Sodium chloride (normal saline or NSS)
Study: NCT00566241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human IGF-1
Description: rhIGF-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03641014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pH Effect on blastocyst formation
Description: to investigate which pH is suitable for each stage of embryo development
Study: NCT00717912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental sweetener syrup
Description: 3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental sweetener syrup
Description: 3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental sweetener syrup
Description: 3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental sweetener syrup
Description: 3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental sweetener syrup
Description: 3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental sweetener syrup
Description: 3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sweetener syrup
Description: 1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sweetener syrup
Description: 1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sweetener syrup
Description: 1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sweetener syrup
Description: 1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sweetener syrup
Description: 1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sweetener syrup
Description: 1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sugar syrup
Description: 3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sugar syrup
Description: 3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
Study: NCT03907475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT00717912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sugar syrup
Description: 3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sugar syrup
Description: 3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sugar syrup
Description: 3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical sugar syrup
Description: 3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
Study: NCT00813072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP02
Description: 120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT00529087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-methylnaltrexone bromide (MOA-728)
Description: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-methylnaltrexone bromide (MOA-728)
Description: Subcutaneous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00323453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open appendectomy using Alexis Wound Retractor followed by standardized wound closure
Description: The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open appendectomy with standardized wound closure
Description: The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
Study: NCT01476839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: basiliximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous hematopoietic progenitor cell infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: yttrium Y 90-labeled basiliximab
Description: Given IV
Study: NCT03956563

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Youlaser MT Group 2
Description: Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the control arm will receive 3 simulated laser treatments every 30 days.~A placebo consists in a sham device laser that simulates the acoustic signal even if it does not deliver any laser radiation to the subject.
Study: NCT01191450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg
Description: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Higroton® Laboratório Novartis
Description: Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
Study: NCT04117477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Xylitol dental wipes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dental wipes
Study: NCT01034683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lobaplatin , 5-FU ,leucovorin
Description: Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
Study: NCT01513447

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intracutaneous injections
Description: Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracutaneous injections
Description: Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
Study: NCT00093743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO or IV